The latest update is out from VolitionRX ( (VNRX) ).
On April 22, 2025, VolitionRx Limited entered a Capital On Demand Sales Agreement with JonesTrading Institutional Services LLC, allowing the company to sell up to $7.5 million of its common stock. This agreement replaces a prior arrangement with Jefferies LLC and aims to support VolitionRx’s research, product development, and potential strategic acquisitions. The termination of the previous agreement with Jefferies LLC, effective April 20, 2025, marks the end of the prior program, and no further sales will be made under it.
Spark’s Take on VNRX Stock
According to Spark, TipRanks’ AI Analyst, VNRX is a Underperform.
VolitionRX’s overall stock score is low due to significant financial challenges, including negative equity and cash flow issues. Technical indicators show a weak momentum, and traditional valuation metrics are unfavorable. Despite promising revenue growth and strategic initiatives highlighted in the earnings call, the company’s financial instability and execution risks weigh heavily on the stock’s outlook.
To see Spark’s full report on VNRX stock, click here.
More about VolitionRX
VolitionRx Limited operates in the biotechnology industry, focusing on developing blood-based diagnostic tests to detect various cancers and other diseases. The company is dedicated to advancing its research and product development, clinical studies, and commercialization efforts.
YTD Price Performance: -24.13%
Average Trading Volume: 169,556
Technical Sentiment Signal: Strong Buy
Current Market Cap: $48.16M
For detailed information about VNRX stock, go to TipRanks’ Stock Analysis page.